Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma

[1]  A. A. Morozov,et al.  Modern approaches to kidney cancer immunotherapy , 2018, Cancer Urology.

[2]  Z. Shao,et al.  Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. , 2018, Journal of Cancer.

[3]  Juan Wang,et al.  High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma , 2018, Translational oncology.

[4]  A. Osunkoya,et al.  Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma , 2017, Oncoimmunology.

[5]  T. Whiteside,et al.  Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients , 2017, Clinical Cancer Research.

[6]  C. Scapulatempo Neto,et al.  PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival , 2017, Melanoma research.

[7]  J. Li,et al.  The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta‐analysis , 2017, Scandinavian journal of immunology.

[8]  J. Lang,et al.  Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer , 2017, Oncotarget.

[9]  G. Tse,et al.  PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients , 2017, Breast Cancer Research and Treatment.

[10]  L. Gandhi,et al.  Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.

[11]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[12]  N. Matsumura,et al.  PD-1/PD-L1 blockade in cancer treatment: perspectives and issues , 2016, International Journal of Clinical Oncology.

[13]  C. Porta,et al.  PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. , 2015, Cancer treatment reviews.

[14]  Zhen-hua Hu,et al.  Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. , 2011, Cytokine.

[15]  J. Cheville,et al.  Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma , 2011, Clinical Cancer Research.